Address: Praça São Marcos, 624 05455-050 – São Paulo – SP,Brazil
Tel: 0800-772-4656
Web: http://www.ferring.com.br/
In 1950 in Malmö, Sweden, Dr. Frederik Paulsen founded Laboratoriet Nordiska hormone, which in 1954 changed its name to Ferring.
A world leader in peptide hormones, Ferring was a pioneer in developing and selling pharmaceutical products based on natural hormones, the pituitary-produced peptide. Dr. Paulsen was convinced that these new compounds could be used to supplement deficiencies and abnormalities, making an invaluable role in the treatment of various diseases.
Five decades later, Dr. Paulsen’s predictions have proven inaccurate. Today, the peptides are widely used in various treatments of Ferring.
Over the past years Ferring has expanded its activities beyond its European base and now have subsidiaries operating in over 40 countries, including Brazil, which is the company’s fastest-growing subsidiary. Its annual turnover is 700 million and has over 3,000 employees. Over the next three to five years, the group aims to triple sales in Brazil.
Propess, BioGaia, DDAVP, Choragon, Bravelle, FemLab, Menogon
An overview of some of the biggest stories from Latin American pharma and healthcare, including Brazil’s rollout of dengue vaccines following a sharp increase in cases; the Brazilian regulatory agency…
A roundup of some of the latest stories from Latin American pharma and healthcare, including Sanfer’s acquisition of Columbia-based injectables manufacturer Vitalis; medicine shortages in Colombia, and Chile’s move towards…
Brazil’s ANVISA is commonly recognised as LatAm’s leading national medicines regulator and is defined by the Pan American Health Organization (PAHO) as a National Regulatory Authority of Regional Reference (NRAr) for medicines…
The latest pharma news from Brazil, including the partnership between Biophytis and Innovation Solutions Pharma; Merck’s 100 years in Brazil; Eurofarma’s USD 100 million biotech investment, and GSK’s green light…
A roundup of some of the latest news from Latin American pharma, including Acino’s acquisition of M8 Pharmaceuticals; AstraZeneca’s growth in Mexico; Neuraxpharm’s expansion into Brazil and Mexico, and Columbia’s…
The DIA Global Annual Meeting 2023 hosted DIA’s first regulatory Town Hall fully dedicated to one regulator from Latin America, as leadership from Brazil’s Health Regulatory Agency, ANVISA, shared updates on the…
The latest pharma news from Brazil, including Daiichi Sankyo’s new plant; Bristol Myers Squibb’s re-entry into Brazil’s cardiology market; the Anvisa approval of HIV prevention drug, cabotegravir; Merck’s gamble on…
A vibrant and diverse continent, home to over 650 million people and the highest life expectancy among developing regions, Latin America is now emerging as a globally relevant life sciences…
Having spent 25 years in the rare disease arena, Maria Gabriella Pittis now finds herself at the forefront of a different field, spearheading the launch of Takeda’s dengue vaccine across…
As the COVID-19 pandemic showed, vaccines are humanity’s best weapon in the fight against infectious diseases. Nowhere is this more evident than Latin America, where specific climatic, geographic, and social…
Henrique Tada of ALANAC, the association that brings together Brazil’s domestic pharma companies, comments on the evolution of the Brazilian generics, biosimilars, and value-added medicines markets, local laboratories’ internationalisation efforts,…
In a wide-ranging interview, AbbVie’s Flavio Devoto outlines some of the key access challenges and opportunities in the diverse Latin American pharma market, his approach to being a transformational leader…
See our Cookie Privacy Policy Here
